CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 9 enrolled
Drug / intervention
G-colony stimulating factor +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01503749
NCT01503749Phase 1Completed
CompareCT.gov

The Role of Peripheral Mononuclear Cells for Treatment of Advanced Liver Cirrhosis

Seoul National University Hospital·interventional·Posted Jan 4, 2012·Updated Dec 19, 2014

In Brief

A Phase 1 clinical trial evaluating G-colony stimulating factor and Infusion of the mobilized monocyte cells for Liver Cirrhosis. Completed, enrolled 9 participants.

Detailed Summary

The investigators aim to investigate the safety and efficacy of peripheral blood monocyte for the treatment of patients with advanced liver cirrhosis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLiver Cirrhosis
Countries--
Collaborators--

Timeline

Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJan 4, 2012
Enrollment StartJan 1, 2012
Primary CompletionJul 1, 2013
Study CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 14.5 years ago

Interventions

G-colony stimulating factordrug

G-colony stimulating factor (5ug/kg/day)will be administered subcutaneously to three patients with liver cirrhosis of this arm.

Infusion of the mobilized monocyte cellsother

G-colony stimulating factor (5ug/kg/day)will be administered twice subcutaneously for 3 days to three patients with liver cirrhosis of this arm. On the day 4th, leukapheresis will be done to collect peripheral blood mononucleated cells. And then we are going to infuse the collected peripheral blood mononucleated cells of their own through the portal vein of each patients under ultrasonographic guidance.